Search

EU pilot on drug repurposing

Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines. As stated in EHA’s position paper on access to affordable orphan medicines (Merlini et al.

Read more

Highlights of Past EHA (HOPE) Asia 2020

October 16-17 2020
Meeting Chairs:

Dr N Senadheera (Sri Lanka College of Haematologists)
Prof J Gribben (European Hematology Association)

This second edition of HOPE Asia was presented together with the Sri Lanka College of Haematologists (SLCH) on October 16 and 17, 2020.…

Read more

Pediatric Hematology

The SWG on Pediatric Hematology has several key goals for the next four years (2024–2026):

To further develop our role as the voice of pediatric hematology within EHA
To reach out to YEHA pediatric hematologists to develop educational material to underpin our…

Read more

Highlights of Past EHA (HOPE) EMEA 2020

Highlights of Past EHA (HOPE) EMEA 2020
October 9-10, 2020
Meeting Chairs:

Prof J Gribben (European Hematology Association)
Prof GH Özsan

In the second weekend of October, EHA and the Turkish Society of Hematology (TSH) kicked-off the very first virtual HOPE meeting.…

Read more

EHA undersigns Manifesto on Treatment Optimization

EHA has given its formal endorsement to the “Manifesto for a new approach for better medicine in Europe: Establishing Treatment Optimization as part of personalized medicine development”.

Read more

The February 2018 - Volume 2 - Issue 1 of HemaSphere is now available online

The February 2018 - Volume 2 - Issue 1 of HemaSphere is now available online. HemaSphere is an open access journal, powered by the European Hematology Association and dedicated to support hematology patient care, research and education worldwide.

Read more

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).

Read more